Singapore, Aug 26, 2010: Having displayed fluctuating growth rates in the years 2005-2009, the Taiwan pharma market is expected to stabilize and starting from 2010 will show the slight deceleration in growth over the years up to 2014, says a new report from Research and Markets.
The Taiwan pharma market generated total revenues of $3.9 billion in 2009, representing a compound annual growth rate (CAGR) of 6.5 percent for the period spanning 2005-2009. In comparison, the Chinese and Japanese markets grew with CAGRs of 20.1 percent and 2.3 percent respectively, over the same period, to reach respective values of $23.8 billion and $66.89 billion in 2009.
Alimentary/metabolism sales proved the most lucrative for the Taiwan pharma market in 2009, generating total revenues of $507.1 million, equivalent to 13 percent of the market's overall value. In comparison, cardiovascular sales generated revenues of $493.5 million in 2009, equating to 12.6 percent of the market's aggregate revenues.
| 
Comment on this article
